Fairpointe Capital’s Ovid Therapeutics OVID Stock Holding History

Fairpointe Capital’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$288K	Sell	71,700 -50,000	-41%	-$166K	0.43%	65
2020 Q4	$281K	Hold	121,700	–	–	0.05%	68
2020 Q3	$699K	Sell	121,700 -5,000	-4%	-$33.5K	0.11%	55
2020 Q2	$934K	Sell	126,700 -15,000	-11%	-$70.2K	0.14%	56
2020 Q1	$422K	Hold	141,700	–	–	0.06%	61
2019 Q4	$588K	Buy	141,700 +40,700	+40%	+$129K	0.05%	60
2019 Q3	$327K	Hold	101,000	–	–	0.02%	70
2019 Q2	$187K	Hold	101,000	–	–	0.01%	75
2019 Q1	$179K	Buy	101,000 +60,000	+146%	+$150K	0.01%	77
2018 Q4	$99K	Buy	+41,000	New	+$187K	﹤0.01%	83

Other funds holding OVID

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fairpointe Capital's OVID Position: Q1 2021 in Review

Fairpointe Capital reduced its Ovid Therapeutics (OVID) stake by 41% in Q1 2021, selling an estimated $166K and leaving 71,700 shares worth $288K. The position accounts for 0.43% of the portfolio, ranked #65.

Fairpointe Capital first reported a position in OVID in Q4 2018 and has held it in 10 quarters since. The position peaked at $934K in Q2 2020. 88 funds tracked by Wall St. Rank hold OVID as of Q1 2021.

Fairpointe Capital held 71,700 shares of Ovid Therapeutics worth $288K as of Q1 2021.
Fairpointe Capital sold 50,000 Ovid Therapeutics shares in Q1 2021, an estimated $166K.
Ovid Therapeutics made up 0.43% of Fairpointe Capital's portfolio in Q1 2021, its #65 holding.
Fairpointe Capital first reported a position in Ovid Therapeutics in Q4 2018 and has held it in 10 quarters since.
Fairpointe Capital's Ovid Therapeutics position peaked at $934K in Q2 2020.
88 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2021.

Based on Fairpointe Capital's 13F filing for Q1 2021, filed 13 May 2021.